Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Biovail enters into an agreement with Santhera to develop and market JP-1730/fipamezole drug

Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into an agreement with Santhera Pharmaceuticals (Switzerland) Ltd., a subsidiary of Santhera Pharmaceuticals Holding AG (SIX: SANN) to acquire the U.S. and Canadian rights to develop and commercialize Santhera’s JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson’s Disease (DPD). JP-1730/ fipamezole is a first-in-class compound that, in a recent Phase IIb study, displayed the potential to reduce levodopa-induced dyskinesia.

24 Aug 2009

Nervous system integrity could play a central role in preventing prion diseases

A new study shows that nervous system integrity and axonal properties may play a key role in prion diseases. The findings, from researchers at the Rudolf Virchow Center and the Institute of Virology of the University of W-rzburg, expand our understanding of the development of prion disease and suggest novel targets for therapeutic and diagnostic approaches in its early stages.

24 Aug 2009

Real Americans share experiences, common need for patient-centric reform

Teva Pharmaceuticals USA, the world's leading generic pharmaceutical company, today announced the start of its "Patient First" project as part of the Year of Affordable Healthcare campaign. The initiative, available at: www.yearofaffordablehealth.com/patients, features a first-hand perspective of everyday Americans as they struggle with the enormous and sometimes insurmountable expense of paying for their prescription medicines.

21 Aug 2009

Role of HPRT genes detected in Lesch Nyan X-linked inherited disorders

A study from the Center for Molecular Genetics at the University of California, San Diego School of Medicine shows that a gene called HPRT plays an important role in setting the program by which primitive or precursor cells decide to become normal nerve cells in the human brain. This unconventional view of metabolic genes known as "housekeeping" genes is now online at the journal Molecular Therapy.

21 Aug 2009

Omnicomm's TrialMaster EDC solution chosen by Impax Pharmaceuticals for study in Parkinson's disease

OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that Impax Pharmaceuticals, the brand division of Impax Laboratories, Inc., Hayward, CA, has selected the TrialMaster EDC solution for conducting a Phase III study in patients with Parkinson's Disease. "While managing a global multi site clinical trial there can be significant challenges in getting trial data when you want it and in the format that you need it," said Suneel Gupta, PhD, Chief Scientific Officer for Impax. "The TrialMaster EDC solution provides us with an intuitive and easy to use export tool that simplifies the process. After considering multiple different EDC solutions, we selected OmniComm Systems based on its customer driven approach and reputation for delivering unparalleled service and support. Additionally, its support of industry standards has enabled us to meet our very tight corporate timelines for this important study."

21 Aug 2009

Coping with burn injuries

More than half a million Americans are treated for burn injuries every year, but many do not have the specific skills necessary to cope with the experience of living with a burn injury after they leave the hospital.

20 Aug 2009

Mesenchymal stem cells repair human brain

There is no known cure for neurodegenerative diseases such as Huntington's, Alzheimer's and Parkinson's. But new hope, in the form of stem cells created from the patient's own bone marrow, can be found ― and literally seen ― in laboratories at Tel Aviv University.

20 Aug 2009

The Parkinson's Disease Foundation and the Davis Phinney Foundation jointly fund new study

The Davis Phinney Foundation, a non-profit organization dedicated to improving the lives of people with Parkinson's disease (PD) today, announced that it has awarded four Parkinson's disease research centers with support to conduct a landmark study on the long-term changes in quality of life and mobility that occur in people with PD. The results of this research will help to advance the understanding of how interventions, such as exercise, impact changes in quality of life and mobility over the course of the disease.

19 Aug 2009

George Rehm and David Mahoney joins Adamas' Board of Directors

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has closed a $40 million Series D round of funding led by aeris CAPITAL AG and DAG Ventures. Earlier investors MDV-Mohr Davidow Ventures and Northgate Capital also participated in the round. In conjunction with the financing, the company announced the election of George M. Rehm, Managing Partner of aeris CAPITAL AG, and David L. Mahoney, a private equity investor, to the company's Board of Directors.

19 Aug 2009

American Asthma Foundation awards $750,000 to Dr.Charles Zuker

Dr. Charles Zuker, a renowned expert on the nerves that determine taste and smell, has been awarded $750,000 by the American Asthma Foundation (AAF). Dr. Zuker will apply his expertise to asthma by defining the nerves that contract the airways during an asthma attack in order to reduce the severity of these episodes.

19 Aug 2009

Smoking increases risk for brain shrinkage in multiple sclerosis

People who smoke and have multiple sclerosis (MS) may be at increased risk of brain shrinkage and increased brain lesions related to the disease, according to a study published in the August 18, 2009, print issue of NeurologyÂ®, the medical journal of the American Academy of Neurology. Smoking has already been linked to an increased risk of developing MS.

18 Aug 2009

When cell death goes wrong - scientists gain new insights

Medical Research Council (MRC) scientists have made an important advance in understanding the biological processes involved when cells are prompted to die. The work may help scientists to eventually develop new treatments for the many common diseases and conditions which occur when cell death goes wrong.

13 Aug 2009

Smell and taste disorders can be treated

When flowers aren’t fragrant and spicy foods don’t zing, the senses may be impaired. But don’t assume that diminished senses of taste and smell are due to aging, says the August issue of Mayo Clinic Women’s HealthSource.

13 Aug 2009

Amsterdam Molecular Therapeutics reports 2009 half year financials

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2009.

13 Aug 2009

$3.2M grant to explore how chemicals affect human health

Most people would agree that arsenic, lead, mercury, benzene and carbon monoxide pose dangers to humans. Not many, though, realize that the average person is exposed to about 10,000 different chemicals per day.

12 Aug 2009

Despite officials' efforts to clear air, fears about end-of-life care remain

Rumors and controversy continue to swirl around end-of-life issues and health care reform as President Barack Obama and others try to calm fears.

12 Aug 2009

Children with newly diagnosed epilepsy at risk for cognitive problems

Children who have normal IQs before they experience a first seizure may also have problems with language, memory, learning and other cognitive skills, according to a study published in the August 12, 2009, online issue of Neurology, the medical journal of the American Academy of Neurology.

12 Aug 2009

Transgenomic reports Q2 2009 financials

The Company reported a net loss of $730,000 or $0.01 per share for the second quarter of 2009 as compared to net income of $101,000 or $0.00 per share for the second quarter of 2008.

12 Aug 2009

Neurologix announces Q2 2009 financials

Neurologix, Inc. (OTCBB:NRGX) announced today its financial results for the second quarter and six months ended June 30, 2009.

12 Aug 2009

Depomed reports promising results in phase I trial for DM-1992 in Parkinson’s

Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson’s patients, DM-1992, Depomed’s investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa’s efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.

11 Aug 2009